HOLLISTON, Mass., Aug. 24, 2016 /PRNewswire/ -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today announced that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY. Jim McGorry, CEO of Biostage will present on Monday, September 12, 2016 at 3:00 p.m. EDT.
As part of his presentation, Mr. McGorry will outline Biostage's expected upcoming near-term corporate, clinical and regulatory milestones that will enable the Company's transition to a clinical-stage company in the coming months.
Mr. McGorry will discuss the Company's recent advancements including the previously announced positive, confirmatory proof-of-concept pre-clinical results demonstrating successful esophagus regeneration in the study conducted with Mayo Clinic. He will also provide an update on the pre-clinical studies required by the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) submission for the Company's lead product candidate, the Cellspan™ Esophageal Implant and additional pre-clinical large-animal studies being conducted in collaboration with Mayo Clinic which are focused on the Company's bronchial implant technology.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the presentation will be available on the Events page of the Investor Relations section of the Company's website (www.biostage.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.
Biostage is a biotechnology company developing bioengineered organ implants based on the company's new Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan™ organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.
Cellspan implants are currently being advanced and tested in collaborative pre-clinical studies. Pre-clinical, large-animal safety studies, conducted in compliance with the FDA Good Laboratory Practice (GLP) regulations, for the Company's Cellspan Esophageal Implant product candidate have begun, in support of Biostage's goal of filing an Investigational New Drug (IND) application with the U.S. FDA in late 2016. The IND will seek approval to initiate clinical trials for its esophageal implant product candidate in humans.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing our Cellframe technology, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for our products; plus other factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biostage-to-present-at-the-18th-annual-rodman--renshaw-global-investment-conference-on-september-12-2016-300317344.html
SOURCE Biostage, Inc.